Literature DB >> 11184803

Incorporating option values into the economic evaluation of health care technologies.

S Palmer1, P C Smith.   

Abstract

Despite uncertainty being intrinsic to economic evaluation of health care, existing techniques for handling uncertainty remain underdeveloped compared to the formal techniques commonly applied in the business sector. This paper develops an alternative approach to handling uncertainty in economic evaluation based on 'option-pricing' techniques. The presence of uncertainty and the degree of irreversibility of a decision make it clear that some flexibility in the timing of a decision is often a desirable characteristic with an economic value. We demonstrate how option-pricing techniques can be applied to the decision rules for economic evaluation in health care. The key determinants of an option value are the presence and type of uncertainty; the ability to defer a decision; and the irreversibility of the decision. The relative significance of each of these for a particular economic evaluation will depend on the particular characteristics of the technology under consideration.

Mesh:

Year:  2000        PMID: 11184803     DOI: 10.1016/s0167-6296(00)00048-5

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  13 in total

1.  Population- versus cohort-based modelling approaches.

Authors:  Olivier Ethgen; Baudouin Standaert
Journal:  Pharmacoeconomics       Date:  2012-03       Impact factor: 4.981

2.  When to wait for more evidence? Real options analysis in proton therapy.

Authors:  Janneke P C Grutters; Keith R Abrams; Dirk de Ruysscher; Madelon Pijls-Johannesma; Hans J M Peters; Eric Beutner; Philippe Lambin; Manuela A Joore
Journal:  Oncologist       Date:  2011-12-06

Review 3.  Role of pharmacoeconomic analysis in R&D decision making: when, where, how?

Authors:  Paul Miller
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

4.  Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research.

Authors:  Kalipso Chalkidou; Andrew Hoy; Peter Littlejohns
Journal:  J R Soc Med       Date:  2007-10       Impact factor: 5.344

5.  An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography.

Authors:  Paolo Pertile
Journal:  Int J Health Care Finance Econ       Date:  2009-01-18

6.  Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.

Authors:  Adrian Towse; Louis P Garrison
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

7.  Exploring uncertainty in cost-effectiveness analysis.

Authors:  Karl Claxton
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

8.  The timing of adoption of positron emission tomography: a real options approach.

Authors:  Paolo Pertile; Emanuele Torri; Luciano Flor; Stefano Tardivo
Journal:  Health Care Manag Sci       Date:  2009-09

9.  Cost-effectiveness acceptability curves revisited.

Authors:  Maiwenn J Al
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

Review 10.  A systematic and critical review of the evolving methods and applications of value of information in academia and practice.

Authors:  Lotte Steuten; Gijs van de Wetering; Karin Groothuis-Oudshoorn; Valesca Retèl
Journal:  Pharmacoeconomics       Date:  2013-01       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.